EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Do the benefits of IDH mutations in high-grade glioma persist beyond the first recurrence? A multi-institutional retrospective analysis

Anne R Lally, Sayak R Ghosh, Isabella L Pecorari, Joshua Reynolds, Alexander Ledet, Sabrina Begley, Elizabeth Juarez Diaz, Eric Zhu, Karan Joseph, Kyle McGeehan, Michael Schulder, Tanner Johanns und 2 weitere

Journal of Neuro-Oncology · 2025

DOI: 10.1007/s11060-025-05049-2 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Neuro-Oncology, 2025. Verfasst von Anne R Lally und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, Montefiore Medical Center, The University Hospital for the Albert Einstein College of Medicine, 3316 Rochambeau A…. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Brain Neoplasms, Mutation, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Recurrence is inevitable in both IDH wild-type glioblastoma and IDH-mutant WHO grade 3 or 4 astrocytoma. While IDH-mutant astrocytomas are associated with longer survival and delayed first progression, less is known about disease course beyond initial treatment. This study examines whether IDH mutation status influences time to second recurrence and identifies additional predictors of recurrence intervals.

Methods

This retrospective, multi-institutional study included adults diagnosed with pathologically confirmed high-grade glioma (HGG) between 2015 and 2020. HGG refers to IDH-mutant WHO grade 3 or 4 astrocytomas and IDH wild-type glioblastomas, consistent with WHO CNS5 criteria. Demographics, treatment, extent of resection, and molecular markers were analyzed. Time-to-recurrence was calculated per RANO 2.0 criteria. Statistical tests included Mann‒Whitney U, Fisher’s exact, and Cox regression.

Results

Among 319 patients, 121 met inclusion criteria. Fourteen (11.6%) had IDH-mutant astrocytomas, and 107 (88.4%) had IDH wild-type glioblastomas. Mean time to first recurrence was significantly longer in IDH-mutant patients (17.5 months) than IDH wild-type (9.8 months, p = 0.0130). Mean time-to-second recurrence was not significantly different (IDH-mutant: 10.8 months, IDH wild-type: 8.1 months, p = 0.176). Multivariate analysis found IDH wild-type status (p = 0.0491) and Black race (p = 0.0238) predicted shorter time to first recurrence.

Conclusions

IDH mutation status significantly affects time to first but not second recurrence. This study offers insight into recurrence patterns and highlights disparities in disease progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseBrain NeoplasmsMutationNeoplasm Recurrence, LocalGliomaHumansFemaleMaleRetrospective StudiesMiddle AgedAdultAgedFollow-Up StudiesPrognosisYoung AdultNeoplasm Grading

Stichwörter der Autor:innen

GlioblastomaIDHMulti-institutionalProgressionRecurrence

Substanzen

Isocitrate DehydrogenaseIDH1 protein, human

Autor:innen und Institutionen

  • Department of Neurological Surgery, Montefiore Medical Center, The University Hospital for the Albert Einstein College of Medicine, 3316 Rochambeau Avenue, Bronx, NY, USA. anne.lally@einsteinmed.edu.
  • Department of Neurological Surgery, Montefiore Medical Center, The University Hospital for the Albert Einstein College of Medicine, 3316 Rochambeau Avenue, Bronx, NY, USA.
  • Department of Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra Northwell, Hempstead, 500 Hofstra Blvd, NY, 11549, USA.
  • Department of Oncology, Washington University at St. Louis, St. Louis, 660 S Euclid Ave, MO, 63110, USA.
  • Department of Pathology and Laboratory Medicine, Donald and Barbara Zucker School of Medicine at Hofstra Northwell, Hempstead, 500 Hofstra Blvd, NY, 11549, USA.

Zitieren

APA

Lally, A. R., Ghosh, S. R., Pecorari, I. L., Reynolds, J., Ledet, A., Begley, S., Diaz, E. J., Zhu, E., Joseph, K., McGeehan, K., Schulder, M., Johanns, T., Ziemba, Y. C., & Agarwal, V. (2025). Do the benefits of IDH mutations in high-grade glioma persist beyond the first recurrence? A multi-institutional retrospective analysis. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-025-05049-2

Vancouver

Lally AR, Ghosh SR, Pecorari IL, Reynolds J, Ledet A, Begley S, et al. Do the benefits of IDH mutations in high-grade glioma persist beyond the first recurrence? A multi-institutional retrospective analysis. Journal of Neuro-Oncology. 2025. doi:10.1007/s11060-025-05049-2

BibTeX
@article{Lally2025,
  author = {Lally, Anne R and Ghosh, Sayak R and Pecorari, Isabella L and Reynolds, Joshua and Ledet, Alexander and Begley, Sabrina and Diaz, Elizabeth Juarez and Zhu, Eric and Joseph, Karan and McGeehan, Kyle and Schulder, Michael and Johanns, Tanner and Ziemba, Yonah C and Agarwal, Vijay},
  title = {Do the benefits of IDH mutations in high-grade glioma persist beyond the first recurrence? A multi-institutional retrospective analysis},
  journal = {Journal of Neuro-Oncology},
  year = {2025},
  doi = {10.1007/s11060-025-05049-2}
}
Kostenlos starten →